Boulder, Colorado – October 24, 2018- Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, will give an oral presentation at the “A Poly-Pharmacy Approach to Mitigate Acute Radiation Syndrome (ARS)” meeting being held October 25, 2018 at the National Institute of Allergy and Infectious Diseases Conference Center, 5601 Fishers Lane, Rockville, Maryland.…
Read more
Bolder BioTechnology Announces Presentation at Radiation Injury Treatment Conference
Boulder, Colorado – September 6, 2018 – Bolder BioTechnology, Inc. announced today that Dr. Joe Cox, Company President, gave an oral presentation at the “Growth Factors and Other Cytokines for Treatment of Injuries During a Radiation Public Health Emergency” meeting held August 30, 2018 at the National Institute of Allergy and Infectious Diseases Conference Center,…
Read more
Bolder BioTechnology Announces Positive Results from Phase 1 Clinical Trial of BBT-015, a Long-Acting G-CSF Analog, in Healthy Volunteers
Boulder, Colorado – April 27, 2018- Bolder BioTechnology, Inc. announced today that it has completed a Phase 1 clinical trial of BBT-015, a proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, in healthy human volunteers. BBT-015 is being developed as a treatment for chemotherapy-related neutropenia in cancer patients and for Acute Radiation Syndrome. Demonstration that the…
Read more
Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute Radiation Syndrome
BOULDER, Colo., Aug. 2, 2017 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that it has commenced dosing of patients in a Phase 1 clinical trial of its proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, BBT-015. The trial is designed to study the pharmacokinetics, pharmacodynamics, safety and tolerability of single subcutaneous doses of BBT-015 in healthy human subjects. BBT-015 is…
Read more